Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

NCT00802347 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT00802347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00802347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2008
Completion date
May 31, 2014
Enrollment
374 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

delayed graft function, other complication of kidney transplant